At 2-year follow-up , patients in the trimetazidine group ( n = 255 ) showed significant improvements in the incidence ( P = 0.024 ) and severity of angina pectoris , compared with the control group , as well as silent myocardial ischaemia ( P = 0.009 ) and angina pectoris-free survival ( P = 0.011 ) .